Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 2, 2002 - Issue 4
Submit an article Journal homepage
39
Views
13
CrossRef citations to date
0
Altmetric
Review

Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment

David Raben University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
,
Cataldo Bianco University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
,
Barb Helfrich University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
,
Elaine Weng University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
,
Fortunato Ciardiello University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
&
Paul Harari University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, Department of Radiation Oncology, Box 6510, F706, Aurora, CO 80010-0510, USA. [email protected]
Pages 461-471 | Published online: 10 Jan 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Edgar Selzer & Gabriela Kornek. (2013) Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. Expert Review of Clinical Pharmacology 6:6, pages 663-676.
Read now

Articles from other publishers (12)

R.S. Waters & V. Prasad. (2021) How often do highly promising cancer biology discoveries translate into effective treatments?. Annals of Oncology 32:2, pages 136-138.
Crossref
Mateusz Jacek Spałek, Katarzyna Kozak, Anna Małgorzata Czarnecka, Ewa Bartnik, Aneta Borkowska & Piotr Rutkowski. (2020) Neoadjuvant Treatment Options in Soft Tissue Sarcomas. Cancers 12:8, pages 2061.
Crossref
Ayub Karimzadeh, Mohammad Hasanzadeh & Nasrin Shadjou. (2019) Bio-assay: The best alternative for conventional methods in detection of epidermal growth factor. International Journal of Biological Macromolecules 133, pages 624-639.
Crossref
Wolfgang Lilleby, Flavio Solca & Kathrine Røe. (2010) Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates. Oncology Reviews 5:2, pages 119-128.
Crossref
Olivier Dassonville, Alexandre Bozec, Jean Louis Fischel & Gerard Milano. (2007) EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 62:1, pages 53-61.
Crossref
Sankha S. Mitra & Richard Simcock. (2006) Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field. Journal of Clinical Oncology 24:16, pages e28-e29.
Crossref
Adam P. Dicker & Ulrich Rodeck. (2005) Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials. Journal of Clinical Oncology 23:24, pages 5437-5439.
Crossref
Carmel T. Chan, Marianne Z. Metz & Susan E. Kane. (2005) Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Research and Treatment 91:2, pages 187-201.
Crossref
Edward S. Kim. (2004) Cetuximab as a Single Agent or in Combination with Chemotherapy in Lung Cancer. Clinical Lung Cancer 6, pages S80-S84.
Crossref
Xiaodong Shen & Randall H. Kramer. (2004) Adhesion-Mediated Squamous Cell Carcinoma Survival through Ligand-Independent Activation of Epidermal Growth Factor Receptor. The American Journal of Pathology 165:4, pages 1315-1329.
Crossref
Rainer Fietkau. (2004) Stage-III NSCLC: multimodality therapy for inoperable tumours. Lung Cancer 45, pages S113-S123.
Crossref
Daniel M Aebersold, Olfert Landt, Sylvie Berthou, Günther Gruber, Karl T Beer, Richard H Greiner & Yitzhak Zimmer. (2003) Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22:52, pages 8519-8523.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.